Report: Unmet Need Can Trump Modest Data In Quest For Reimbursement
This article was originally published in The Gray Sheet
A higher level of evidence did not correlate well with subsequent payer reimbursement, according to a comparison of the coverage success for devices approved via HDE and PMA conducted by Avalere Health for the Pew Charitable Trusts. Perceptions of unmet need tended to serve a bigger factor for coverage, the report said.
You may also be interested in...
In this second portion of a two-part Q&A with Louis Jacques, he talks to “The Gray Sheet” about the importance of CMS’ growing collaboration with FDA, tensions between national and local Medicare coverage policymaking and the impact of resource constraints on CMS. Jacques left his post as CMS coverage director last month.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.